Диссертация (1139560), страница 44
Текст из файла (страница 44)
Curr Opin Urol. 2017Mar;27(2):99-106. doi: 10.1097/MOU.0000000000000369. PubMed PMID:27906778.119. Gennaro A, ed. 2000. Remington: The Science and Practice of Pharmacy,20th edition. Baltimore, MD: Lippincott Williams and Wilkins.120. Gilmore NJ, Vane JR. Hormones released into the circulation when theurinary bladder of the anaesthetized dog is distended. Clin Sci.
1971Jul;41(1):69-83.121. Ginger Campbell, "Interview with Dr. Steven Novella from The Skeptics'Guide to the Universe". Books and Ideas. Pods in Print. Retrieved 2014-0522.122. Girman CJ, Epstein RS, Jacobsen SJ, et al. Natural history of prostatism:impact of urinary symptoms on quality of life in 2115 randomly selectedcommunity men. Urology 1994;44:825–31.123.
Grothe,D.J. Skepticism2.0 // SkepticalInquirer. —November/December 2009. — Vol. 33.6.124. Gutiérrez M., Martinez V., Cantabrana B. and Hidalgo A. (1994) Genomicand non-genomic effects of steroidal drugs on smooth muscle contraction InVitro.Life Sci. 55, 437-443.308125. Gutiérrez, M., Hidalgo, A, Cantabrana, B. (1995) Possible Involvement ofCalmodulin in the Spasmolytic Effect of Extracts from Sabal serrulata Fruits.Pharmaceutical Sei. 1,403-405.126. Gutierrez M, Garcia de Bow M. J., Cantabrana B. and Hidalgo A.Mechanisms Involved in the Spasmolytic Effect of Extracts From Sabalserrulata Fruit on Smooth Muscle// Gen. Pharmac. Vol.
27, No. 1, pp. 171176, 1996127. Hansen BJ, Meyhoff HH, Nordling J, Mensink HJ, Mogensen P, LarsenEH. Placebo effects in the pharmacological treatment of uncomplicatedbenign prostatic hyperplasia. The ALFECH Study Group. Scand J UrolNephrol. 1996 Oct;30(5):373-7. PubMed PMID: 8936626.128. Harnack LJ, Rydell SA, Stang J. 2001. Prevalence of use of herbalproducts by adults in the Minneapolis/St Paul, Minn, metropolitan area.
MayoClin Proc 76:688-694.129. Harnischfeger G. , Stolze H., Z. Phytother., 10 (1989), pp. 71-76.130. Hatinguais P, Belle R, Basso Y, Ribet JP, Bauer M, et al. 1981.Composition of the hexane extract from Serenoa repens Bartram fruits. TravSoc Pharm Montp 41:253-262.131. Herbal Rx for prostate problems. Consum Rep 2000 65(9):60–62.132. Hiermann A. 1989.
About contents of sabal fruits and their antiinflammatory effect. Arch. Pharm (Weinheim) 322:111-114.133. Hiipakka RA, Zhang HZ, Dai W, Dai Q, Liao S. 2002. Structure-activityrelationships for inhibition of human 5α-reductases by polyphenols. BiochemPharmacol 63:1165-1176.134.
ICH S1A: Guideline on the need for carcinogenicity studies ofpharmaceuticals.135. Ichida S., Moriyama M. and Terao M. Characteristics of Ca influx throughvoltage- and receptor-operated Ca channels in uterine smooth muscle. JPharmac. exp. Ther. 1984. 228, 439-445.309136.
Ignarro LJ, Buga GM, Wei LH, Bauer PM, Wu G, del Soldato P. Role ofthe arginine-nitric oxide pathway in the regulation of vascular smooth musclecell proliferation. Proceedings of the National Academy of Sciences of theUnited States of America. 2001;98(7):4202-4208.137. Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascularsystem: a historical overview. J Physiol Pharmacol. 2002 Dec;53(4 Pt 1):50314. Review.
PubMed PMID: 12512688.138. Ioannidis JPA (2005) Why Most Published Research Findings Are False.PLoS Med 2(8): e124.139. Jacobsen SJ, Girman CJ, Jacobson DJ, et al: Long-term (92-month) naturalhistory of changes in the lower urinary tract severity. BJU Int 86: 248 –250,2000.140. Jindal AK, Pandya K, Khan ID Antimicrobial resistance: A public healthchallenge. Med J Armed Forces India. 2015 Apr;71(2):178-81141. Jommi G, Verotta L, Gariboldi P, Gabetta B. 1988. Constituents of thelipophilic extract of the fruits of Serenoa repens (Bart.) small. Gazz Chim Ital118:823-826.142. Jonler M., Riehman M.
and Bruskewitz R. C. (1994) Benign prostatichyperplasia.Drugs 47, 66-81.143. Karaki H. and Weiss G. B. (1988) Calcium release in smooth muscle. LifeSei. 42, 111-122.144. Khastgir J, Khan A, Speakman M. Acute urinary retention: medicalmanagement and the identification of risk factors for prevention. Nat ClinPract Urol 2007;4:422–31.145. Kinci FA, Benagiano G, Angee I.
Sustained release hormonalpreparations, 1. Diffusion of various steroids through polymer membranes.Steroids 1968; 11: 673.146. Kloss P. Steam vaporizable constituents of pressed juice of Sabalserrulatum(Roem et Schult). Arzneimittelforschung. 1966 Jan;16(1):95-6.310147. Kokkalou E, Souleles C. 1988. Flavonoid constituents of Pelargonium xasperum Enrh. ex Willd. Geraniaceae. Plant Med Phytother 22:247-253.148. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia(BPH) an immune inflammatory disease? Eur Urol 2007;51:1202–16.149. Kramer G, Steiner GE, Handisurya A, et al. Increased expression oflymphocyte-derived cytokines in benign hyperplastic prostate tissue,identification of the producing cell types, and effect of differentially expressedcytokines on stromal cell proliferation. Prostate. 2002;52:43–58.150.
Krieger J.N. Classification, epidemiology and implications of chronicprostatitis in North America, Europe and Asia. Minerva UrolNefrol. 2004Jun;56(2):99-107.151. Lalanne C., Mironneau C., Mironneau J. and Savineau J. P. (1984)Contractions of rat uterine smooth muscle induced by acetylcholine andangiotensin II in Ca2+-free medium.
Br. ]. Pharmac. 81, 317-326.152. Lawson RK. Benign prostatic hyperplasia and growth factors. Sq UrolAusg A 1990; 29: 7.153. Lee JY, Lee SH, Kim SJ, Kim CS, Lee HM, Kim CI, Chung BH. Changein International Prostate Symptom storage subscore after long-term medicaltherapy in BPH patients: finasteride and alpha-blocker combination therapyin men with moderate-to-severe LUTS/BPH in Korea.
Urology. 2011Jan;77(1):171-6154. Lee, K.L.; Peehl, D.M. Molecular and cellular pathogenesis of benignprostatic hyperplasia.J. Urol. 2004, 172, 1784–1791.155. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin,finasteride, or both in benign prostatic hyperplasia. Veterans AffairsCooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl JMed. 1996;335:533–539.156. Levy S.
1998. Can saw palmetto be used to treat benign prostatichypertrophy? Drug Topics 142:53.311157. Litwin MS. A review of the development and validation of the NationalInstitutes of Health Chronic Prostatitis Symptom Index. Urology. 2002Dec;60(6 Suppl):14-8; discussion 18-9. Review. PubMed PMID: 12521581.158. Madersbacher S, Eredics K, Schauer I. A Relevant Midterm (12 Months)Placebo Effect on Lower Urinary Tract Symptoms and Maximum Flow Ratein Male Lower Urinary Tract Symptom and Benign Prostatic Hyperplasia-AMeta-analysis.Urology.2017Aug;106:160-166.doi:10.1016/j.urology.2017.05.011.
Epub 2017 May 12. PubMed PMID:28506862.159. Marberger MJ, Andersen JT, Nickel JC, et al. Prostate volume and serumprostate-specific antigen as predictors of acute urinary retention: combinedexperience from three large multinational placebo-controlled trials. Eur Urol2000;38:563–8.160. Marks LS. Treatment of men with minimally symptomatic benign prostatichyperplasia-pro: the argument in favor. Urology 62 (5), 2003.
P. 781-783.161. Marra J. 2002. The state of dietary supplements--Even slight increases ingrowth are better than no growth at all. Nutraceuticals World, 2002, pages 32,36, 38, 40. Magazine article.162. Martinez E., Gallego J. and Jimenez F. J. (1987) Tratamiento médico delsíndrome de prostatismo. Estudio comparativo. Arch. Esp. Urol.
40, 247-253.163. Martyushev-Poklad A., Petrov V., Dugina J., Epstein O., Sergeeva S. Anovel oral antibody therapeutic for treatment of BPH: primary findings of acontrolled clinical trial. In. Proceedings of the VIIIth International Congressof Andrology (Sae – Chul Kim, Grootegoed J.A., Chemes H.E. eds),Medimond, Bologna, Italy, 2005a:183−8.164. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, HoltgreweHL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM,Waldstreicher J. The effect of finasteride on the risk of acute urinary retentionand the need for surgical treatment among men with benign prostatic312hyperplasia.
Finasteride Long-Term Efficacy and Safety Study Group. N EnglJ Med. 1998 Feb 26; 338(9):557-63.165. McConnell JD, Roehrborn CG, Bautista OM, et al. The longterm effect ofdoxazosin, finasteride, and combination therapy on the clinical progression ofbenign prostatic hyperplasia. N Engl J Med 2003;349:2387–98.166. McNeal JE. Pathology of benign prostatic hyperplasia.
Urol Clin NorthAm. 1990;17:477–486.167. McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care2006;12:S122–8.168. Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I.Incidence rates and risk factors for acute urinary retention: the healthprofessionals followup study. J Urol 1999;162:376–82.169. Mishra VC, Allen DJ, Nicolaou C, et al. Does intraprostatic inflammationhave a role in the pathogenesis and progression of benign prostatichyperplasia? BJU Int 2007;100: 327–31.170.
Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF, for theQUOROM Group. Improving the quality of reports of meta-analyses ofrandomised controlled trials: the QUOROM statement. Lancet 1999;354:1896-1900171. Moore RA. , Mark J. The Effect of Avitaminosis-A on the Prostate. TheJournal of Experimental Medicine. Vol.
64.1936; 1-7172. Moore RA. Benign hypertrophy of the prostate: a morphological study. JUrol 1943; 50: 680.173. Moore RA. Inflammation of the prostate gland. J Urol, 1937;38:173–82.174. Moore RA. The evolution and involution of the prostate gland.. AmericanJournal of Pathology. Vol XII, 1936; 599–614.175. Moore, R.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
